unimelb-nlp/MultiEup-v2 huggingface dataset:
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Maria-Manuel Leitão-Marques
Political group: S-D
Country: Italy
Language: PT

Senhor Presidente, Senhor Comissário, os ativos incorpóreos, como as marcas, os desenhos, os modelos, as patentes e os dados, são cada vez mais importantes na economia do conhecimento dos dias de hoje. As indústrias com utilização intensiva de propriedade intelectual representam quase metade do PIB total e mais de 90 % de todas as exportações da União Europeia. Um dos tipos de patentes mais importantes são as chamadas patentes essenciais, isto é, patentes que protegem tecnologias que foram declaradas essenciais para a aplicação de uma norma técnica, por exemplo, as normas que suportam tecnologias como o 5G, o Wi—Fi e o Bluetooth. No entanto, o mercado atual destas patentes é caracterizado por uma falta de previsibilidade e longas disputas e litígios, o que faz com que seja difícil desenvolver novos produtos inovadores baseados neste tipo de patentes. Infelizmente, a autorregulação não tem sido suficiente para debelar e eliminar estes problemas. Por isso mesmo, o Parlamento defende, neste regulamento, que o Instituto de Propriedade Intelectual da União Europeia deve criar um registo de titulares de patentes essenciais, verificar quais as patentes que são realmente essenciais para uma determinada norma, qual o pagamento justo pela utilização dessa patente e prestar assistência nas negociações entre empresas. Pretendemos assegurar que os utilizadores finais, incluindo as pequenas e médias empresas e os consumidores, beneficiam de produtos baseados nas mais recentes tecnologias normalizadas a preços justos e razoáveis. Esperamos, deste modo, e temos a certeza que a Comissão também, acelerar a inovação e não travá-la, garantindo que tanto os proprietários como os utilizadores de patentes essenciais são mais competitivos nos mercados mundiais.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Vlad-Marius Botoş
Political group: Renew
Country: Germany
Language: RO

Domnule președinte, domnule comisar Breton, stimați colegi, tehnologiile moderne sunt parte a vieții noastre de zi cu zi prin multiplele aplicații pe care le folosim în mod regulat. La baza acestor tehnologii stau, firește, patentele esențiale și este normal ca acestea să fie plătite, iar cei care inventează și pun la dispoziție aceste tehnologii să beneficieze de munca lor. Este însă la fel de firesc ca atunci când plătești dreptul de a folosi o astfel de tehnologie să plătești doar pentru acea parte care este cu adevărat esențială și nu pentru aplicații adiționale de care te poți lipsi. Este așadar nevoie să stabilim reguli clare și mai ales transparență în declararea patentelor, fără a îngrădi cu nimic dreptul la proprietate intelectuală. Nu putem să nu remarcăm disproporția dintre deținătorii de patente, care la ora actuală nu au obligații de transparență clare și pot introduce în prețul licenței ceea ce consideră ei de cuviință, și majoritatea utilizatorilor, fie că sunt întreprinderi mici și mijlocii, fie că sunt mari producători de mașini și unelte. Ca în orice domeniu economic, consider că avem nevoie să respectăm drepturile creatorului, dar trebuie să asigurăm transparența și etichetarea pentru cumpărători.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Reinhard Bütikofer
Political group: Verts/ALE
Country: Italy
Language: EN

Mr President, Commissioner, colleagues, indeed, it is important to create a new regulation in order to overcome the lack of transparency and to stop the long legal battles that we’ve seen in the past. However, the two co-rapporteurs have presented their proposals as if they were just simple, clear, evident and balanced. I’m not convinced, and INTA has not been convinced. Within industry, within Commission, within the political groups in this House, there has been a broad debate about the right balance, and we should not try to hide that, and we should not, Ms Walsmann and Mr Wölken, attack the opposing arguments as just being threadbare. I agree with a lot that has been said by colleague Hübner. She’s been speaking not just for her own person or for her own group in INTA, but for INTA. In particular, the aggregate royalty provisions are not convincing to us, and the question whether the new regulation should just apply to future patents is also not satisfactorily solved. We have concerns that the global competitive situation of our industries will be weakened to the advantage of third-country competitors, and I think we should reconsider.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Raffaele Stancanelli
Political group: ECR
Country: Poland
Language: IT

Signor Presidente, signor Commissario, onorevoli colleghi, l'interazione fra brevetti e norme è fondamentale per l'innovazione e la crescita, poiché i brevetti stimolano la ricerca e lo sviluppo e consentono alle imprese innovative di ottenere utili adeguati sul capitale investito.  Circa l'84 % degli utilizzatori dei brevetti essenziali è costituito da piccole e medie imprese. Per tali motivi, la semplice minaccia di un provvedimento che porti a sospendere la fabbricazione di prodotti con la probabilità di un procedimento giudiziario ha effetti negativi. D'altronde, anche i titolari di brevetti SEP devono sostenere lunghi e costosi procedimenti giudiziari per il riconoscimento dei loro diritti.  Per questo motivo dobbiamo approvare norme che siano in grado di creare condizioni migliori ai fini della prevenzione, della risoluzione e della composizione dei conflitti. Sono convinto che l'istituzione di un registro dei brevetti SEP, di una banca dati centrale elettronica, la valutazione del carattere essenziale dei brevetti SEP, l'istituzione di un meccanismo di risoluzione extragiudiziale delle controversie limitata nel tempo, vadano nella giusta direzione.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Virginie Joron
Political group: ID
Country: Estonia
Language: FR

Monsieur le Président, chers collègues, Monsieur le Commissaire, certains d’entre vous ont rencontré des lobbys, ici à Strasbourg, le mois dernier avec Moderna et BioNtech et cette semaine, vous allez probablement en voir d’autres. FleishmannHillard travaille pour Pfizer et a 63 lobbyistes avec un badge d’accès au Parlement. Medtech Europe, un nouveau lobby du marché du numérique de la santé, a déjà rencontré 40 fois la Commission. Cette commission von der Leyen se finit donc comme elle a commencé: sous le signe de «Big Pharma». Après les milliards de contrats arrangés secrètement avec Pfizer-BioNtech Moderna, CureVac, Gilead, après les doses poubelles gaspillées, voici qu’ils veulent carrément changer la réglementation pharmaceutique en leur faveur. Aujourd’hui, nous parlons des brevets, des certificats complémentaires de protection. Bien sûr, nous sommes pour la recherche en Europe, mais il faut oser dire la vérité: c’est un pansement sur une jambe de bois. Depuis 20 ans, quel industriel a investi dans des chercheurs européens? Le résultat, c’est la production partie en Inde et en Chine, avec le dogme du générique, et des pénuries ici de médicaments essentiels. Alors, le cartel pharmaceutique a trouvé la parade. Pour faire des petits profits, c’est plus facile de créer des pénuries, de faire de l’évasion fiscale, de faire une fausse publication pour tuer un ancien médicament, plus facile de faire des études cliniques de deux mois au lieu de deux ans pour ne pas trouver d’effets secondaires, plus facile de convaincre quelques bureaucrates par un lobbying pernicieux. L’urgence, c’est de reprendre le contrôle de ce secteur. Le bingo de la Covid-19 a court-circuité toutes les procédures habituelles et a engendré de mauvaises habitudes, naïves ou complices, chez certaines autorités. Notre santé ne doit pas devenir une fête foraine où l’illusionniste vous fait les poches et disparaît.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Maxette Pirbakas
Political group: NI
Country: Sweden
Language: FR

Monsieur le Président, Monsieur le Commissaire, ce nouveau paquet législatif sur les brevets essentiels est d’autant plus important que le secteur technologique est essentiel pour la croissance de l’économie européenne, et que la sécurité juridique en est une donnée primordiale. Je ne reviendrai pas sur la polémique concernant les doutes liés à l’inexpérience de l’EUIPO en matière de gestion de brevets, je dis juste que le Parlement européen devrait être impliqué dans le suivi des travaux de l’Office. Sur le fond, je ne peux que saluer l’œuvre législative de la Commission en matière de propriété intellectuelle. La volonté est manifeste de créer un cadre juridique clair et harmonisé, à la fois protecteur des intérêts économiques des entreprises innovantes et des standards internationaux. J’espère en revanche que la Commission se montrera aussi active pour faire respecter la propriété intellectuelle liée aux brevets européens par des États tiers. Il ne faudrait pas que l’effort de renforcement de la propriété intellectuelle, mené par l’Europe et qui profitera aussi aux opérateurs économiques non européens, ne soit assorti d’aucune garantie de réciprocité. Comme souvent avec l’Europe, le problème n’est pas notre habileté à créer de la norme, mais notre capacité à faire en sorte qu’elle ne soit pas contournée ou retournée contre nos intérêts. Bien sûr, demain, je voterai pour ce texte.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Henna Virkkunen
Political group: PPE
Country: Italy
Language: EN

Mr President, Commissioner, dear colleagues, for Europe to stay competitive we need to do more to encourage innovation. This requires continued investment in research, development and innovation. When talking about innovation, the importance of patents needs to be recognised.  Therefore, it is important to maintain a balance between the interests of patent holders and the users of standards. Reducing patent protection will increase risks as it will discourage European companies from participating in the development of global standards by undermining patent protection.  I have to say that this proposed regulation can have a negative impact on Europe’s competitiveness, especially in the development of 5G and 6G technologies, where standard essential patents play a crucial role.  We know that 5G and 6G technologies are extremely important to the EU in developing its strategic autonomy and its global competitive edge in digital technologies. If Europe wants to keep its innovative edge we need to have stable and meaningful intellectual property rights such as patent rights.  I have to say that this proposed compromise does not take into account patent protection and creates too much regulatory burden, especially to the standard essential patent holders.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Beatrice Covassi
Political group: S-D
Language: IT

Signor Presidente, signor Commissario, onorevoli colleghi, certificati protettivi complementari e brevetti essenziali sono gli strumenti giuridici da cui passano innovazione e sviluppo. Vengo dalla regione di Leonardo da Vinci e so bene che ogni giorno nuove invenzioni ci offrono soluzioni inedite. Per questo è fondamentale avere un sistema di brevettazione efficace, trasparente e snello. Se innovare significa fare ricerca, i brevetti hanno il ruolo di incoraggiarla, riconoscendo il genio e assicurando che gli sforzi e gli investimenti effettuati siano ricompensati.  Eppure, ancora oggi in Europa il quadro normativo sulla proprietà intellettuale è opaco e frammentato. Sui certificati complementari, la tutela nazionale risulta inefficace e onerosa. Dopo i brevetti europei è allora urgente avere anche certificati complementari europei. Avanti quindi per un sistema armonizzato, più efficace e trasparente, che nel settore farmaceutico porterà anche vantaggi ai pazienti, in termini di disponibilità di farmaci e prezzi.  Riguardo alle tecnologie di punta, la novità passa dai brevetti essenziali: in settori come il 5G o il Wi-Fi, dove esistono standard riconosciuti, questi brevetti devono anche garantire agli utilizzatori condizioni eque, ragionevoli e non discriminatorie. L'obiettivo è migliorare la circolazione delle innovazioni, dando più strumenti anche alle PMI, che sulla spinta del boom degli oggetti connessi, sono circa l'84 % degli utilizzatori dei brevetti. Il registro europeo e la banca dati centrale rafforzeranno trasparenza e certezza del diritto per tutti.  Cari colleghi, facciamo quindi un passo in avanti per l'innovazione, la nostra qualità della vita e il nostro benessere.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Bart Groothuis
Political group: Renew
Country: Portugal
Language: NL

Voorzitter, commissaris, het is altijd flink oppassen geblazen wanneer de overheid roept dat er ergens geen eerlijke prijs voor wordt betaald. Het middel is dan vaak erger dan de kwaal. Kijk bijvoorbeeld eens naar hoe minister Hugo de Jonge in Nederland de woningmarkt op slot heeft gezet. Zeker, hij dwong lagere huurprijzen af, maar investeerders bouwen nu minder woningen en de markt gaat op slot. Iets soortgelijks is nu aan de hand in Europa op het gebied van patenten. Je zal maar patenthouder zijn. Je zal maar al je kennis en intellectueel eigendom vast hebben gelegd in die patenten en daar je geld mee verdienen, bijvoorbeeld om 5G- en 6G-netwerken aan te leggen in Europa. Zij plukken de vruchten van hun arbeid, het zijn bedrijven zoals Nokia, Ericsson maar ook Philips. Ik zeg: laat Nokia, Ericsson, Philips niet overkomen wat de Nederlandse investeerders in de woningmarkt is overkomen. Voorstellen die bureaucratische lagen aanbrengen, die businessmodellen aantasten van bedrijven en van onze Europese kampioenen, die Chinese verdienmodellen mogelijk in de kaart spelen. Collega’s, zoals we in Holland al eeuwen zeggen: let op uw zaak. Steun morgen onze amendementen om dit voorstel te rationaliseren en steun ons in het verzet tegen dit wetsvoorstel.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: François Thiollet
Political group: Verts/ALE
Language: FR

Monsieur le Président, l’harmonisation des certificats est, après le brevet unitaire, un progrès vers la cohérence des politiques de santé en Europe, et nous en avons besoin. On l’a vu lors de la pandémie de Covid-19, l’accès aux vaccins – d’ailleurs Madame von der Leyen, si vous pouvez nous transmettre vos SMS, on les attend toujours – une union européenne de la santé est indispensable. Nous avons besoin d’une alliance du médicament qui permette à chacune et chacun, quel que soit son pays, quelle que soit sa situation, d’avoir un accès libre et le plus gratuit possible aux médicaments dont il a besoin. Aujourd’hui, c’est plus de 15 millions de personnes qui doivent faire face à un besoin médical non satisfait en raison du prix ou du manque de disponibilité. Mais pourtant, plutôt que de défendre les plus fragiles, certains groupes de cette assemblée défendent au contraire les intérêts des plus puissants, des groupes pharmaceutiques, en proposant de rallonger la durée du brevet de neuf jusqu’à treize ans, alors qu’il faudrait plutôt la réduire pour permettre à tous de pouvoir accéder facilement aux médicaments. Selon que vous serez l’ami des puissants, ou plutôt que vous serez moins l’ami des misérables, vos jugements seront plus ou moins influencés par les lobbies que vous fréquentez. Nous avons besoin d’un système qui soit plus juste, plus transparent, où la priorité est la santé de tous plutôt que le profit de quelques-uns.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Miapetra Kumpula-Natri
Political group: S-D
Country: France
Language: EN

Mr President, Commissioner, dear colleagues, I think this is a crucial file. It is not technical, even if it seems like that. I am not very happy with what has been the outcome of this file because I think it really endangers the future of the Europe's position as a telecom pioneer. I didn't hear a word mentioned here on the strategic autonomy. I didn't hear a word mentioning the critical infrastructure. On these days, we cannot forget critical infrastructure as telecom sector is very vital for us to see forward. So I think this is not a balanced version when we talk about the holders and licence providers. So I think hurrying here can do damage for European Union innovative R&D. Also, I think, for example, the explanation on the retroactivity, how can you say that, ‘please invest in Europe, but we are doing the retroactive legislation and we are overlooking that this would even change the existing patent agreements’? So, for me, it was very good that the chair of the JURI Committee has amended this one to find it more balanced. And I really thought that it is not a party political question, that we will find a balanced outcome and look at these previously mentioned big vital questions for Europe. I think Europe, who was the champion in 2G, 3G, 4G, is doing it in 5G. We cannot forget that and find something more balanced for 6G and Europe to be champion.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Ondřej Kovařík
Political group: Renew
Country: Finland
Language: CS

Pane předsedající, pane komisaři, v posledních letech dostává evropský průmysl celkem zabrat. Evropským firmám Evropská unie navyšovala byrokracii, moc jim nepomohla ani s vysokými cenami energií a v boji proti nekalé konkurenci ze třetích zemí. Tak se to pokusme alespoň trochu napravit podporou inovací.  Dnes diskutujeme návrh, který má zlepšit podmínky využívání licencí a patentů, které jsou zásadní pro technologický rozvoj, inovace a budoucí růst firem. Průmysl v této oblasti trápí časté právní spory a vysoké licenční poplatky. Technické normy jsou přitom stále častěji využívány v širokém spektru průmyslových odvětví od automobilového průmyslu přes platební terminály až po inteligentní zařízení. Standardy mají být dostupné co nejširšímu okruhu subjektů, včetně malých a středních podniků, a to i prostřednictvím jasně definovaných licenčních podmínek. Musíme tedy zavést spravedlivé a nediskriminační podmínky pro takové licence. To pomůže společnostem lépe konkurovat na globální úrovni, zejména vůči asijským rivalům. Tato opatření umožní evropským firmám získat licence na technologie bez zbytečných překážek a soutěžit na globálních trzích za rovných podmínek.
Debate: Unitary supplementary protection certificate for plant protection products - Unitary supplementary certificate for medicinal products - Supplementary protection certificate for plant protection products  - Supplementary protection certificate for medicinal products  - Standard essential patents
Date: TUESDAY, 27 FEBRUARY 2024
Speaker: Billy Kelleher
Political group: Renew
Country: Denmark
Language: EN

Mr President, this proposed regulation on standard essential patents has become fairly controversial and divisive over the last few weeks. Let’s strip it back to what the objectives of such a proposal should be: one, establishing a framework that will ultimately benefit the consumer, either by lowering the cost of these technologies, increasing the availability of technologies, or simply improving the technologies; and two, fostering innovation.  And we have to ask ourselves in the area of fostering innovation with regard to the EU, there are severe regulatory obstacles and EU bureaucracy, and we cannot allow this to become the international or public perception of the European Union. We need to be known as a place where innovation can thrive and deliver on these commitments. Is it against this backdrop that we need to assess the set proposal? Does it strike the right balance between consumer interests and industrial interests? Will it foster innovation? Will it ease the process of establishing a patent or licensing a patent?  I would encourage my colleagues not to get entrenched in the position of one company or another, but to take a step back and assess the proposal on the basis of what is in the best interests of the EU market.